New Hope for Tourette's as Novel Drug Enters Expanded Access Program

CHICAGO, IL – March 09, 2026 – For families navigating the unpredictable and often disruptive reality of Tourette syndrome, the search for an effective and tolerable treatment can be a long and frustrating journey. Today, a new avenue of hope has opened as Emalex Biosciences announced that the first patient has been dosed in its Expanded Access Program (EAP) for ecopipam, an investigational therapy with a novel mechanism of action. The program provides a pathway for patients who have exhausted currently approved treatments to access the drug outside of a formal clinical trial.

This development marks a significant step for a community in dire need of new options. The EAP, registered on ClinicalTrials.gov as NCT07093541, is slated to enroll approximately 200 patients at sites across the United States, offering a potential lifeline to those for whom existing medications have failed, caused intolerable side effects, or are otherwise inaccessible.

A Lifeline for Patients with Unmet Needs

Tourette syndrome (TS) is a complex, childhood-onset neurodevelopmental disorder characterized by involuntary motor and vocal tics. These tics can range from mild to severe, profoundly impacting a person's education, social development, and overall quality of life. The condition is often accompanied by comorbidities such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Obsessive-Compulsive Disorder (OCD), further complicating treatment and daily life.

Expanded Access Programs, sometimes called “compassionate use,” are regulated by the U.S. Food and Drug Administration (FDA) to provide investigational medicines to patients with serious conditions who cannot participate in a clinical trial. Eligibility for Emalex’s program is specifically for patients who have been treated with an FDA-approved therapy—such as haloperidol, pimozide, or aripiprazole—but have experienced treatment failure or significant safety and tolerability concerns.

“Tourette syndrome can profoundly disrupt a child’s education, social development and quality of life, and many families struggle to find effective, well-tolerated treatments,” said Dr. Frederick Munschauer, chief medical officer of Emalex Biosciences, in a statement. “We established this Expanded Access Program to help address that gap while ecopipam continues to advance through development.”

For decades, the pharmacological treatment of Tourette syndrome has been dominated by antipsychotic medications that carry a heavy side effect burden. This new program offers a tangible possibility for patients and their clinicians who have been left with few, if any, viable alternatives.

Shifting the Paradigm: Beyond D2 Receptor Blockade

What sets ecopipam apart is its fundamental approach to treating Tourette syndrome. It is a first-in-class investigational therapy that selectively blocks the dopamine-1 (D1) receptor. This mechanism is a distinct departure from currently approved treatments, which primarily act as antagonists to the dopamine-2 (D2) receptor.

The scientific rationale behind this approach is based on the theory that supersensitivity of D1 receptors may be a key driver of the repetitive and compulsive behaviors associated with the disorder. By targeting D1 receptors, ecopipam aims to address a core mechanism of tics without impacting the D2 pathways linked to many of the most challenging side effects of current therapies.

Standard D2-blocking antipsychotics, while effective for some, are notorious for causing adverse effects such as significant weight gain, metabolic issues like high cholesterol and diabetes, extreme sedation, and the risk of permanent, drug-induced movement disorders like tardive dyskinesia. These side effects often lead to poor adherence and discontinuation of treatment, particularly in a pediatric population.

Ecopipam, which is not an antipsychotic, represents a potential paradigm shift. By avoiding the D2 receptor, it may offer a more favorable safety and tolerability profile, a critical factor for a chronic condition that begins in childhood and often requires long-term management.

A Foundation of Promising Clinical Data

The decision to launch an EAP is supported by a growing body of encouraging clinical data. Ecopipam has been studied in multiple trials, including a pivotal Phase 2b study and a recent Phase 3 registrational trial, both of which demonstrated its potential efficacy and a manageable safety profile.

In the Phase 2b D1AMOND study, ecopipam showed a statistically significant 30% reduction in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) compared to placebo. Crucially, the data suggested that the drug was generally well tolerated, with the most common side effects being headache, insomnia, fatigue, and somnolence. Importantly, the study found no evidence of the excessive weight gain or metabolic side effects commonly associated with D2-targeting antipsychotics.

More recently, topline data from the Phase 3 D1AMOND study reinforced these findings. The trial met its primary endpoint, showing that ecopipam significantly reduced the rate of relapse in both pediatric and adult patients with Tourette syndrome. The safety profile remained consistent with previous studies, further building confidence in the drug’s potential as a long-term treatment option.

Recognizing its potential to address a significant unmet medical need, the FDA has granted ecopipam both Orphan Drug and Fast Track designations for the treatment of pediatric patients with Tourette syndrome. These designations are designed to help expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

Navigating a Challenging Treatment Landscape

The development of new therapies for neurological disorders is notoriously difficult, and the Tourette syndrome pipeline has seen its share of setbacks. Other investigational drugs, including some VMAT2 inhibitors, have failed to meet their primary endpoints in recent clinical trials for TS, highlighting the immense challenge of bringing a new treatment to market. If ultimately approved, ecopipam would be one of the first truly novel medicines for Tourette syndrome in decades.

The launch of the Expanded Access Program provides a regulated and monitored bridge for patients in the interim. Participation requires oversight from a physician, authorization from the FDA, and approval from an Institutional Review Board (IRB), ensuring patient safety remains paramount. While enrollment is limited and determined on a case-by-case basis, the program represents a crucial step forward for the community.

For physicians who treat Tourette syndrome, the availability of ecopipam through this program offers a much-needed option for their most challenging cases. It allows them to provide a potential new therapy based on a novel scientific approach, free from the difficult trade-offs that have defined the treatment landscape for so long. As ecopipam continues its journey through the final stages of clinical development, this program provides immediate, tangible hope to patients and families who need it most.